Abstract
Boehringer Ingelheim is involved in the manufacturing and marketing of human
pharmaceuticals (prescription medicines, consumer health care products),
products for industrial customers (chemicals and biopharmaceuticals) and
animal health. This report provides a full review of the company's activities
together with sales forecasts for key products to 2010.
Boehringer Ingelheim GmbH is the world's largest private pharmaceutical
enterprise, encompasses more than 152 affiliates in 45 countries, and
employing over 34,000 people. The company's activities are concentrated on two
businesses: Human Pharmaceuticals and Animal Health.
Within the Prescription Medicines division, BI markets products in the
following therapeutic areas: Respiratory, Cardiovascular, Immunology and
Inflammation, Urology, Central Nervous System and Virology. Research and
development is focused on developing treatments in the following fields:
Respiratory, Cardiovascular, Immunology and Inflammation, Central Nervous
System, Virology, Metabolic and Oncology.
Current Growth Drivers
Three of BI's current major products are forecast by Espicom to have sales in
excess of EUR 1 billion by 2010, forming the foundations of short to medium
growth in the prescription pharmaceutical sector.
- Spiriva (tiotropium bromide) is a novel, once-daily, inhaled treatment for
chronic obstructive pulmonary disease.
- Micardis (telmisartan) is an angiotensin-II receptor blocker for the
once-daily treatment of hypertension.
- Mobic (meloxicam) is a non-steroidal anti-inflammatory drug for the
treatment of rheumatoid arthritis and osteoarthritis.
View Cart
